|
Novo Nordisk( NovoNordisk) created a new generation of GLP-1( glucagon-like peptide 1) analogue known as somallutide( semaglutide). Somalutide has more advantages when managing type 2 diabetes because of its fundamental platform. Its medicine class has a long-acting side effect. On December 5, 2016, Novo Nordisk submitted an application for marketing authorization( MAA) to the European Medicines Agency( EMA). There have been six completed PChemicalbookhaseIIIa somutide picture research. On the other hand, the somaglutide once-daily development is in the works. 【キーワード】 Semaglutide |
---|